• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of drugs for cerebral amyloidosis with novel mechanisms of action using DDS technology

Research Project

Project/Area Number 16H05223
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Research Field Applied pharmacology
Research InstitutionKumamoto University

Principal Investigator

ARIMA HIDETOSHI  熊本大学, 大学院生命科学研究部(薬), 教授 (50260964)

Co-Investigator(Kenkyū-buntansha) 東 大志  熊本大学, 大学院先導機構, 准教授 (20613409)
本山 敬一  熊本大学, 大学院生命科学研究部(薬), 准教授 (50515608)
Research Collaborator Yokoyama Ryoma  
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2018: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2017: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2016: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Keywords脳アミロイドーシス / シクロデキストリン / デンドリマー / 結合体 / ドラッグデリバリーシステム / アミロイド溶解作用 / 血液脳関門 / 脳移行性 / る脳アミロイドーシス / DDS / BBB / 脳移行 / 鼻脳移行 / DDS技術 / 脳ターゲティング
Outline of Final Research Achievements

So far, the number of patients with dementia has been increasing, especially Alzheimer's disease (AD) will be more serious. However, there is no curative treatments to AD, so development of new therapeutic agents is strongly desired. In this study, brain-targeting PAMAM dendrimer/cyclodextrin conjugate (BT-CDE conjugate) was prepared and was found to simultaneously regulate not only the formation and accumulation of amyloid fibrils but also accumulation of cholesterol in cells. In addition, intravenous administration of BT-CDE conjugate to mice showed higher brain-localizing properties than CDE conjugate. These results suggest that BT-CDE may have the potential as new drug seeds for AD.

Academic Significance and Societal Importance of the Research Achievements

本研究で見出したラクトシル化CDE結合体は、患者数の増加が予想されているアルツハイマー病に対して、これまでに開発されてきた化合物とは化学構造が全く異なり、また、ADに関わる複数の因子を同時に制御可能な全く新規の治療薬シーズとなりうる可能性が示された。この研究成果はすでに特許出願を行っており、日本初のAD治療薬になりうることが期待される。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Annual Research Report
  • 2016 Annual Research Report
  • Research Products

    (3 results)

All 2019 2018 Other

All Presentation (1 results) Remarks (1 results) Patent(Industrial Property Rights) (1 results)

  • [Presentation] 脳アミロイドーシス治療薬としてのデンドリマー/シクロデキストリン結合体の可能性評価2019

    • Author(s)
      横山龍馬、小野寺理沙子、東 大志、本山敬一、有馬英俊
    • Organizer
      日本薬学会第139年会
    • Related Report
      2018 Annual Research Report
  • [Remarks]

    • URL

      http://www.pharm.kumamoto-u.ac.jp/Labs/seizai/index.html

    • Related Report
      2017 Annual Research Report
  • [Patent(Industrial Property Rights)] 脳移行性リガンドおよび薬物担体2018

    • Inventor(s)
      有馬英俊; 本山敬一; 東大志; 小野寺理沙子; 横山龍馬
    • Industrial Property Rights Holder
      国立大学法人熊本大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2018-245538
    • Filing Date
      2018
    • Related Report
      2018 Annual Research Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi